Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine

Neurobiol Dis. 2000 Feb;7(1):54-63. doi: 10.1006/nbdi.1999.0271.

Abstract

Mutations in presenilin 1 (PS1) are the most common causes of familial Alzheimer's disease (FAD). We examined synaptic physiology in hippocampal brain slices of transgenic mice expressing the FAD-linked PS1 deletion of exon 9 variant. Basal excitatory transmission and paired-pulse facilitation in PS1 mutant mice were unchanged. Short- and long-term potentiation of excitatory transmission following high-frequency stimulation were greater in transgenic mice expressing mutant PS1. Mutants had enhanced synaptic inhibition, which may be a compensatory change offsetting an abnormally sensitized plasticity of excitatory transmission. Increasing inhibitory transmission in mutant animals even more with a benzodiazepine reverted synaptic potentiation to the levels of controls. These results support the potential use of benzodiazepines in the treatment of familial Alzheimer's disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alzheimer Disease / genetics*
  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Electric Stimulation
  • Excitatory Postsynaptic Potentials / drug effects
  • Excitatory Postsynaptic Potentials / physiology*
  • Exons
  • Flunitrazepam / pharmacology*
  • GABA-A Receptor Antagonists
  • Genetic Variation
  • Hippocampus / drug effects
  • Hippocampus / physiology*
  • Hippocampus / physiopathology
  • Humans
  • In Vitro Techniques
  • Membrane Proteins / genetics*
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Presenilin-1
  • Sequence Deletion
  • Synapses / drug effects
  • Synapses / physiology*

Substances

  • Anti-Anxiety Agents
  • GABA-A Receptor Antagonists
  • Membrane Proteins
  • PSEN1 protein, human
  • Presenilin-1
  • Flunitrazepam